What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline.

Carbapenem-resistant Enterobacteriaceae present an increasing and diverse problem, including strains of multiple species with metallo-β-lactamases (IMP, NDM or VIM) and non-metallo (KPC and OXA-48) enzymes as well as those combining an extended-spectrum β-lactamase (ESBL) or AmpC enzyme with porin loss. Most strains, except those with OXA-48 alone, are broadly resistant to β-lactams and have multiple aminoglycoside-modifying enzymes; those with NDM-1 carbapenemase typically also have 16S rRNA methylases, conferring complete aminoglycoside resistance. In this study, the activity of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline was evaluated against 81 carbapenem-resistant Enterobacteriaceae isolates from the UK. Testing was performed by the Clinical and Laboratory Standards Institute (CLSI) agar dilution method. Chloramphenicol, ciprofloxacin and nitrofurantoin inhibited <25% of the isolates at the breakpoint, whereas colistin was active against 75/81 isolates (92.6%), the exceptions being four Klebsiella pneumoniae and Enterobacter cloacae isolates along with members of inherently resistant genera. Fosfomycin was active against 49/81 isolates (60.5%), including 7/7 Escherichia coli, 16/20 Enterobacter and Citrobacter spp., but only 25/52 Klebsiella spp. Tigecycline was active against 38/81 isolates (46.9%) and was intermediate against another 27 (33.3%), with resistance scattered amongst K. pneumoniae and Enterobacter spp. The activity of colistin, fosfomycin and tigecycline was unrelated to the isolates' carbapenem resistance mechanisms. Temocillin was fully active [minimum inhibitory concentration (MIC) ≤8 mg/L] against only 4/81 isolates (4.9%), but inhibited a further 22 isolates (27.2%) at the British Society for Antimicrobial Chemotherapy (BSAC) urinary breakpoint (32 mg/L), predominantly comprising those isolates with combinations of impermeability and an ESBL or AmpC enzyme, along with 6/11 isolates producing KPC carbapenemases. Studies with transconjugants and transformants confirmed the small effect of KPC enzymes against temocillin, whereas OXA-48 and NDM-1 conferred clear resistance.

[1]  D. Sofianou,et al.  Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 beta-lactamase resistant to colistin. , 2010, The Journal of hospital infection.

[2]  D. Paterson,et al.  Activity of Temocillin against KPC-Producing Klebsiella pneumoniae and Escherichia coli , 2009, Antimicrobial Agents and Chemotherapy.

[3]  N Woodford,et al.  Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. , 2011, The Journal of antimicrobial chemotherapy.

[4]  I. Damjanova,et al.  Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[5]  P. Nordmann,et al.  The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. , 2009, The Lancet. Infectious diseases.

[6]  H. Bonatti Tigecycline for Treatment of Pneumonia and Empyema Caused by Carbapenemase-Producing Klebsiella pneumoniae , 2008 .

[7]  N. Woodford,et al.  Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study , 2010, The Lancet. Infectious diseases.

[8]  M. Falagas,et al.  Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. , 2010, The Lancet. Infectious diseases.

[9]  A. Vatopoulos High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece--a review of the current evidence. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[10]  J. Turnidge,et al.  Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. , 2006, The Lancet. Infectious diseases.

[11]  H. Nikaido,et al.  Porin channels in Escherichia coli: studies with beta-lactams in intact cells , 1983, Journal of bacteriology.

[12]  Y. Chuang,et al.  Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. , 2010, Diagnostic microbiology and infectious disease.

[13]  C. Nicolaou,et al.  Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. , 2009, The Journal of infection.

[14]  N. Woodford,et al.  Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing Enterobacteriaceae , 2010, Antimicrobial Agents and Chemotherapy.

[15]  A. Levin,et al.  Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  P. Nordmann,et al.  Spread of OXA-48-Encoding Plasmid in Turkey and Beyond , 2010, Antimicrobial Agents and Chemotherapy.